AMRI sees 50% jump in FY revenue from Gadea Pharma acquisition

Albany Molecular Research Inc (Nasdaq: AMRI) on Tuesday said it expects the  acquisition of Spanish firm Gadea Pharmaceutical to add over 50% to its full year contract revenue and over 40% for adjusted per share earnings.

The company in a statement said it sees full year contract revenue between $386 million and $400 million up 56% at the midpoint. It expects royalty revenue of between $14 million and $16 million, including about $5.5 million of Allegra royalties, which have now expired.

The USA-based drugmaker said it sees adjusted diluted per share earnings of $0.90 to $0.95, compared with $0.65 in 2014. Estimates for adjusted earnings before income tax depreciation and amortization stand at between $75 million and $78 million, up 53% at the midpoint. AMRI sees annual capital expenditure of between $24 million and $26 million.